Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Expected to Announce Earnings of $0.70 Per Share

Analysts predict that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will post $0.70 earnings per share (EPS) for the current quarter, Zacks reports. Eight analysts have made estimates for Neurocrine Biosciences’ earnings. The lowest EPS estimate is $0.51 and the highest is $0.92. Neurocrine Biosciences reported earnings per share of $0.19 during the same quarter last year, which suggests a positive year-over-year growth rate of 268.4%. The company is expected to issue its next quarterly earnings results on Tuesday, February 4th.

According to Zacks, analysts expect that Neurocrine Biosciences will report full-year earnings of $0.70 per share for the current year, with EPS estimates ranging from $0.50 to $0.95. For the next financial year, analysts forecast that the business will post earnings of $3.35 per share, with EPS estimates ranging from $2.23 to $4.55. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.56 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.07). The firm had revenue of $222.09 million during the quarter, compared to analyst estimates of $211.31 million. Neurocrine Biosciences had a net margin of 3.12% and a return on equity of 5.67%. The company’s quarterly revenue was up 46.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.52 EPS.

Several equities research analysts have recently commented on NBIX shares. Credit Suisse Group upped their target price on Neurocrine Biosciences from $95.00 to $110.00 and gave the company an “outperform” rating in a report on Tuesday, July 30th. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a report on Wednesday, July 31st. BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Friday, November 8th. TheStreet raised Neurocrine Biosciences from a “c+” rating to a “b” rating in a report on Tuesday. Finally, Royal Bank of Canada set a $118.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a report on Friday, September 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $106.94.

Shares of Neurocrine Biosciences stock traded up $0.67 during trading on Monday, hitting $113.75. The stock had a trading volume of 698,100 shares, compared to its average volume of 807,274. The company has a debt-to-equity ratio of 0.83, a current ratio of 7.08 and a quick ratio of 6.99. The firm has a market cap of $10.41 billion, a P/E ratio of 517.05, a PEG ratio of 5.72 and a beta of 1.20. The business has a fifty day moving average of $99.77 and a two-hundred day moving average of $91.57. Neurocrine Biosciences has a fifty-two week low of $64.72 and a fifty-two week high of $116.06.

In related news, insider Darin Lippoldt sold 1,664 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $100.09, for a total transaction of $166,549.76. Following the transaction, the insider now directly owns 21,625 shares of the company’s stock, valued at $2,164,446.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dimitri E. Grigoriadis sold 5,000 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $115.98, for a total value of $579,900.00. Following the transaction, the insider now directly owns 113,408 shares in the company, valued at $13,153,059.84. The disclosure for this sale can be found here. Insiders have sold 57,795 shares of company stock worth $5,911,988 over the last three months. 4.30% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of the business. Comerica Bank increased its position in Neurocrine Biosciences by 3.3% in the 3rd quarter. Comerica Bank now owns 3,933 shares of the company’s stock worth $386,000 after purchasing an additional 125 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Neurocrine Biosciences by 2.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 6,265 shares of the company’s stock worth $565,000 after acquiring an additional 135 shares in the last quarter. M&T Bank Corp boosted its stake in shares of Neurocrine Biosciences by 4.7% during the 2nd quarter. M&T Bank Corp now owns 3,377 shares of the company’s stock worth $286,000 after acquiring an additional 153 shares in the last quarter. JGP Global Gestao de Recursos Ltda. boosted its stake in shares of Neurocrine Biosciences by 5.6% during the 3rd quarter. JGP Global Gestao de Recursos Ltda. now owns 3,097 shares of the company’s stock worth $279,000 after acquiring an additional 163 shares in the last quarter. Finally, Virginia Retirement Systems ET AL boosted its stake in shares of Neurocrine Biosciences by 1.2% during the 3rd quarter. Virginia Retirement Systems ET AL now owns 17,000 shares of the company’s stock worth $1,532,000 after acquiring an additional 200 shares in the last quarter. 95.02% of the stock is currently owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Further Reading: The risks of owning bonds

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.